Bioheart

About:

Bioheart is a biotech company that focuses on the development of effective cell technologies to treat cardiovascular diseases.

Website: http://www.bioheartinc.com

Twitter/X: BioheartInc

Top Investors: Rogers Communications, BioMedPartners, Magna, Advent-Morro Equity Partners, Magellan Bioscience Group

Description:

Bioheart, Inc. is dedicated to advancing the field of regenerative medicine by offering the highest quality technology, cellular treatments and training. Specific to biotechnology, Bioheart, Inc. specializes in the discovery, development and commercialization of autologous cellular therapies that treat a wide variety of degenerative diseases. Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry by delivering stem cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, chronic and acute heart damage, peripheral vascular disease and other issues. Bioheart's goals are to improve a patient’s quality of life by regenerating their damaged tissue, when possible, and by reducing health care costs and hospitalizations. Bioheart’s leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.

Total Funding Amount:

$19.9M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Sunrise, Florida, United States

Founded Date:

1999-01-01

Contact Email:

bioheart(AT)bioheartinc.com

Founders:

Howard Leonhardt, William P. Murphy

Number of Employees:

11-50

Last Funding Date:

2014-10-24

IPO Status:

Delisted

Industries:

© 2025 bioDAO.ai